LCGC
MRNA icon

Legacy Capital Group California’s Moderna MRNA Stock Holding History

Legacy Capital Group California’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,719
Closed -$204K – 339
2024
Q2 		$204K Buy
+1,719
New +$218K 0.07% 291
2023
Q3 		– Sell
-1,731
Closed -$210K – 289
2023
Q2 		$210K Buy
1,731
+67
+4% +$8.94K 0.09% 254
2023
Q1 		$256K Buy
+1,664
New +$275K 0.12% 206

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Legacy Capital Group California's MRNA Position: Q3 2024 in Review

Legacy Capital Group California sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,719 shares — an estimated $204K sold.

Legacy Capital Group California first reported a position in MRNA in Q1 2023 and held it in 3 quarters. The position peaked at $256K in Q1 2023. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Legacy Capital Group California reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Legacy Capital Group California sold 1,719 Moderna shares in Q3 2024, an estimated $204K.
  • Legacy Capital Group California first reported a position in Moderna in Q1 2023 and held it in 3 quarters.
  • Legacy Capital Group California's Moderna position peaked at $256K in Q1 2023.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Legacy Capital Group California's 13F filing for Q3 2024, filed 23 Oct 2024.